# Espire Hospital (NSE: ESPIRE) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/ESPIRE · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹274 Cr, it ranks 2105th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Resorts & Casinos.

Its return on equity was 19.0% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹43 Cr (+5.0% year on year) and net profit ₹4 Cr (−6.0%), on a standalone basis. Promoters held 69.25% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹274 Cr |
| ROE | 19.0% (FY25) |
| ROCE | 11.6% (FY25) |
| Debt to equity | 1.68 |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹43 Cr | +5.0% | ₹4 Cr | −6.0% | ₹2.84 |
| Q3 FY26 | ₹41 Cr | −0.5% | ₹8 Cr | +193.5% | ₹6.07 |
| Q2 FY26 | ₹19 Cr | −6.9% | −₹6 Cr | −694.8% | −₹3.81 |
| Q1 FY26 | ₹32 Cr | +90.7% | ₹1 Cr | +4,666.7% | ₹1.04 |
| Q4 FY25 | ₹41 Cr | +310.8% | ₹4 Cr | +483.1% | ₹3.26 |
| Q3 FY25 | ₹41 Cr | +259.4% | ₹3 Cr | +213.5% | ₹2.07 |
| Q2 FY25 | ₹20 Cr | +317.7% | ₹1 Cr | +380.0% | ₹0.71 |
| Q1 FY25 | ₹17 Cr | +74.3% | ₹0 Cr | −95.7% | ₹0.02 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹120 Cr | ₹8 Cr |
| FY24 | ₹36 Cr | ₹3 Cr |
| FY23 | ₹19 Cr | ₹0 Cr |
| FY22 | ₹2 Cr | −₹0 Cr |
| FY21 | ₹0 Cr | −₹1 Cr |
| FY20 | ₹0 Cr | −₹0 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 69.25%
- Foreign institutions: 2.08%
- Non-institutions: 28.67%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Astonea Labs](https://app.pivotnow.in/stock/ASTONEALAB) | — | ₹281 Cr | — | — |
| [Ambalal Sarabhai Enterprises](https://app.pivotnow.in/stock/AMBALALSA) | ₹36.20 | ₹277 Cr | 15.6 | — |
| [Zenotech Labs](https://app.pivotnow.in/stock/ZENOTECH) | — | ₹270 Cr | — | — |
| [Everest Organic](https://app.pivotnow.in/stock/EVERESTO) | — | ₹262 Cr | — | — |
| [Gennex Labs](https://app.pivotnow.in/stock/GENNEX) | — | ₹254 Cr | — | — |
| [Kerala Ayur](https://app.pivotnow.in/stock/KERALAYUR) | — | ₹254 Cr | — | — |

## Questions and answers

### What is the market cap of Espire Hospital?

Espire Hospital's market capitalisation is ₹274 Cr (₹274 Cr) at the 22 Oct 2026 close, ranking 2105th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Espire Hospital?

Return on equity was 19.0% in FY25 and return on capital employed was 11.6% in FY25 (standalone figures).

### Is Espire Hospital a debt-free company?

No. Espire Hospital's debt-to-equity ratio was 1.68 in FY25, with total debt of ₹70 Cr.

### What were Espire Hospital's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Espire Hospital reported revenue of ₹43 Cr, +5.0% year on year, and net profit of ₹4 Cr, −6.0% year on year.

### What is the shareholding pattern of Espire Hospital?

As of 30 Jun 2026: promoters 69.25%, foreign institutions 2.08%, non-institutions 28.67%.

### Who are Espire Hospital's competitors?

The listed Pharma & Healthcare companies closest to Espire Hospital by market cap are Astonea Labs, Ambalal Sarabhai Enterprises, Zenotech Labs, Everest Organic, Gennex Labs and Kerala Ayur.

### Is Espire Hospital a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Espire Hospital's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ESPIRE against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.